791
5The role of AI in drug discovery and delivery stands at a pivotal juncture. The integration of advanced computational approaches is not just an emerging trend but a fundamental shift in how we approach the creation of new therapeutics.
My guest for this week’s episode is Chris, Co-Founder & Product Lead at Nanograb, a YC biotech company (YC S23) that uses AI to generate the best combination of binders to treat different diseases.
Prior to co-founding Nanograb, Chris had a career in HSBC Hong Kong. Chris has a master degree in Biomaterials and Tissue Engineering at Imperial College London. His experience across biotech, finance and entrepreneurship give his unique insights you won’t want to miss.
-
Join us this episode to hear about:
- 00:59 Chris’ early upbringing and connection with his entrepreneurial drive
- 07:38 Chris’ gravitation from finance toward entrepreneurship
- 17:53 The founding team
- 26:08 About Nanograb
- 31:31 Chris’ YC experience
- 38:12 Chris’ view on hiring
- 42:04 Advice to 20-year old self
-
☕️ References:
- Y Combinator: a startup accelerator that invests in a wide range of startups.
- AlphaFold: an artificial intelligence program developed by DeepMind, a subsidiary of Alphabet, which performs predictions of protein structure. Having revealed millions of intricate 3D protein structures, it is helping scientists understand how all of life's molecules interact.
-
☕️ About Us:
- Victoria: Management Consultant | VC | Entrepreneur | Imperial College London Chemistry alum | 🔗 LinkedIn
- Jecci: Documentary Filmmaker | Cambridge MPhil Social Anthropology alum | 🔗 LinkedIn
-
☕️ Production Team:
Host: Victoria
Audio Editing: Jeff
-
☕️ Disclaimer:
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any fund.
